The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis

Gut

Volumn 59, Issue 7, 2010, Pages 943-952

  Albillos, Agustín ^a,b,c   Nieto, Mónica ^a,c   Ubeda, María ^a,c   Muñoz, Leticia ^a,c   Fraile, Benito ^a   Reyes, Eduardo ^a,c   Lledó, Lourdes ^a   Blanco, Ignacio ^b   Pastor, Óscar ^b   Salas, Clara ^d   Lario, Margaret ^a,c   Monserrat, Jorge ^a,c   Bataller, Ramón ^c,e   Álvarez Mon, Melchor ^a,c,f  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GAMMA INTERFERON; HYDROXYPROLINE; IMMUNOFERON; INTERLEUKIN 10; INTERLEUKIN 4; MESSENGER RNA; PLACEBO; PROCOLLAGEN ALPHA1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSLOCATION; BILIARY CIRRHOSIS; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FIBROGENESIS; HEMODYNAMIC MONITORING; HYPEREMIA; IMMUNE RESPONSE; INTERFERON PRODUCTION; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MONOCYTE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CALCIUM PHOSPHATES; CYTOKINES; DRUG EVALUATION, PRECLINICAL; GLYCOPEPTIDES; IMMUNOMODULATION; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MONOCYTES; RATS; RATS, WISTAR; T-LYMPHOCYTE SUBSETS;

EID: 77953989191     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.168831     Document Type: Article

References (42)

1. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539-48.
2. Iredale JP. Regulating hepatic inflammation: pathogen-associated molecular patterns take their toll. Hepatology 2003;37:979-82.
3. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-74.
4. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208-17. (Pubitemid 36042162)
5. Albillos A, de la Hera A, Reyes E, et al. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol 2004;40:624-31. (Pubitemid 38367784)
6. Muñoz L, Albillos A, Nieto M, et al. Mesenteric Th1 polarization and monocyte TNF-alpha production: first steps to systemic inflammation in rats with cirrhosis. Hepatology 2005;42:411-19.
7. Kerfoot SM, D'Mello C, Nguyen H, et al. TNF-alpha-secreting monocytes are recruited into the brain of cholestatic mice. Hepatology 2006;43:154-62.
8. Albillos A, Muñoz L, Nieto M, et al. Systemic effects of TNF-alpha secreted by circulating monocytes and fatigue in cirrhosis. Hepatology 2006;43:1399.
9. Tazi KA, Moreau R, Hervé P, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 2005;129:303-14. (Pubitemid 41002062)
10. Albillos A, de la Hera A, Álvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004;363:1608-10.
11. Chin-Dusting JP, Rasaratnam B, Jennings GL, et al. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med 1997;127:985-8.
12. Muñoz J, Albillos A, Pérez-Páramo M, et al. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol 1999;276:G687-93.
13. López-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-7.
14. Eigler A, Matschke V, Hartmann G, et al. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor. J Leukoc Biol 2000;68:97-103.
15. Jørgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 2003;57:93-8.
16. Naveau S, Chollet-Martín S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:1390-7.
17. Pérez-García R, Pérez-García A, Verbeelen D, et al. AM3 (Inmunoferón) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Kidney Int 2002;61:1845-52.
18. Álvarez-Mon M, Miravitlles M, Morera J, et al. Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest 2005;127:1212-18.
19. Varela J, Navarro Pico ML, Guerrero A, et al. Identification and characterization of the peptidic component of the immunomodulatory glycoconjugate Immunoferon. Methods Find Exp Clin Pharmacol 2002;24:471-80.
20. Sidwell RW, Huffman JH, Barnard DL, et al. Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. Antiviral Res 1994;25:105-22.
21. Reyes E, Prieto A, de la Hera A, et al. Treatment with AM3 restores defective T-cell function in COPD patients. Chest 2006;129:527-35.
22. Prieto A, Reyes E, Bernstein ED, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferón). Am J Respir Crit Care Med 2001;163:1578-83.
23. Martín-Vilchez S, Molina-Jiménez F, Alonso-Lebrero JL, et al. AM3, a natural glycoconjugate, induces the functional maturation of human dendritic cells. Br J Pharmacol 2008;154:698-708.
24. Brieva A, Guerrero A, Alonso-Lebrero JL, et al. Immunoferon, a glycoconjugate of natural origin, inhibits LPS-induced TNF-alpha production and inflammatory responses. Int Immunopharmacol 2001;1:1979-87.
25. Brieva A, Guerrero A, Pivel JP. Inmunoferon, a glycoconjugate of natural origin, regulates the liver response to inflammation and inhibits TNF-alpha production by an HPA axis-dependent mechanism. Int Immunopharmacol 2002;2:807-13. (Pubitemid 34603125)
26. Crispe IN. Isolation of mouse intrahepatic lymphocytes. Curr Protoc Immunol 2001; Chapter 3:Unit 3.21:3.21.1-3.21.8.
27. Hogan MM, Vogel SN. Measurement of tumor necrosis factor alpha and beta. Curr Protoc Immunol 2001;Chapter 6:Unit 6.10.
28. Ruwart MJ, Wilkinson KF, Rush BD, et al. The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat. Hepatology 1989;10:801-6.
29. Ebrahimkhani MR, Kiani S, Oakley F, et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 2006; 55:1606-16.
30. Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-94.
31. Sancho-Bru P, Bataller R, Fernandez-Varo G, et al. Bradykinin attenuates hepatocellular damage and fibrosis in rats with chronic liver injury. Gastroenterology 2007;133:2019-28.
32. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
33. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999;104:1223-33. (Pubitemid 29536293)
34. Mora JR, von Andrian UH. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 2006;27:235-43.
35. Majano P, Alonso-Lebrero JL, Janczyk A, et al. AM3 inhibits LPS-induced iNOS expression in mice. Int Immunopharmacol 2005;5:1165-70.
36. Aggarwal BB, Samanta A, Feldmann M. TNF-alpha. In: Oppenheim JJ, Feldmann M, eds. Cytokine reference. A compendium of cytokines and other mediators of host defense. Academic Press: New York: 2000:413.
37. Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology 1990;11:599-605.
38. Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989;84:1780-5.
39. Imamura M, Ogawa T, Sasaguri Y, et al. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 2005;128:138-46.
40. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56-65.
41. Kinnman N, Francoz C, Barbu V, et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 2003;83:163-73. (Pubitemid 36255362)
42. Díaz R, Kim JW, Hui JJ, et al. Evidence for the epithelial to mesenchymal transition in biliary atresia fibrosis. Hum Pathol 2008;39:102-15.